Intraperitoneal chromic phosphate in ovarian cancer

Risks and benefits

Mark E. Potter, Edward E. Partridge, Hugh M. Shingleton, Seng Jaw Soong, Robert Y. Kim, Kenneth D Hatch, J. Maxwell Austin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

Original languageEnglish (US)
Pages (from-to)314-318
Number of pages5
JournalGynecologic Oncology
Volume32
Issue number3
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Neoplasms
Reoperation
Laparotomy
Morbidity
Recurrence
Therapeutics
chromic phosphate

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Potter, M. E., Partridge, E. E., Shingleton, H. M., Soong, S. J., Kim, R. Y., Hatch, K. D., & Austin, J. M. (1989). Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits. Gynecologic Oncology, 32(3), 314-318. https://doi.org/10.1016/0090-8258(89)90631-8

Intraperitoneal chromic phosphate in ovarian cancer : Risks and benefits. / Potter, Mark E.; Partridge, Edward E.; Shingleton, Hugh M.; Soong, Seng Jaw; Kim, Robert Y.; Hatch, Kenneth D; Austin, J. Maxwell.

In: Gynecologic Oncology, Vol. 32, No. 3, 1989, p. 314-318.

Research output: Contribution to journalArticle

Potter, ME, Partridge, EE, Shingleton, HM, Soong, SJ, Kim, RY, Hatch, KD & Austin, JM 1989, 'Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits', Gynecologic Oncology, vol. 32, no. 3, pp. 314-318. https://doi.org/10.1016/0090-8258(89)90631-8
Potter, Mark E. ; Partridge, Edward E. ; Shingleton, Hugh M. ; Soong, Seng Jaw ; Kim, Robert Y. ; Hatch, Kenneth D ; Austin, J. Maxwell. / Intraperitoneal chromic phosphate in ovarian cancer : Risks and benefits. In: Gynecologic Oncology. 1989 ; Vol. 32, No. 3. pp. 314-318.
@article{d45cdea5ea3341a48ee86746813ca4be,
title = "Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits",
abstract = "Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated {"}secondarily{"} after tumor recurrence or after a {"}positive{"} second-look laparotomy. Associated morbidity was noted to be 12{\%} with reoperation required in 7{\%}. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in {"}secondary{"} therapy of advanced stage and grade tumors.",
author = "Potter, {Mark E.} and Partridge, {Edward E.} and Shingleton, {Hugh M.} and Soong, {Seng Jaw} and Kim, {Robert Y.} and Hatch, {Kenneth D} and Austin, {J. Maxwell}",
year = "1989",
doi = "10.1016/0090-8258(89)90631-8",
language = "English (US)",
volume = "32",
pages = "314--318",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Intraperitoneal chromic phosphate in ovarian cancer

T2 - Risks and benefits

AU - Potter, Mark E.

AU - Partridge, Edward E.

AU - Shingleton, Hugh M.

AU - Soong, Seng Jaw

AU - Kim, Robert Y.

AU - Hatch, Kenneth D

AU - Austin, J. Maxwell

PY - 1989

Y1 - 1989

N2 - Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

AB - Between March 1977 and December 1985, 59 patients were treated with intraperitoneal chromic phosphate at The University of Alabama Birmingham Hospitals and its affiliates. Twenty-seven patients received primary adjuvant therapy. Thirty-two patients were treated "secondarily" after tumor recurrence or after a "positive" second-look laparotomy. Associated morbidity was noted to be 12% with reoperation required in 7%. Early stage and grade tumors demonstrate a good prognosis. Little, if any, benefit was demonstrated in "secondary" therapy of advanced stage and grade tumors.

UR - http://www.scopus.com/inward/record.url?scp=0024561357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024561357&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(89)90631-8

DO - 10.1016/0090-8258(89)90631-8

M3 - Article

VL - 32

SP - 314

EP - 318

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -